Drugs / stannsoporfin

Trials 11

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00004397 Jan 1998 → May 2000 porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 1 NCT00004398 Jan 1998 → May 2000 porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00004789 Jul 1993 → ? porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 26 trials · 1 met primary
Phase 2 NCT01887327 Oct 2013 → Mar 2016 hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Completed Met primary
Phase 2 NCT00850993 Aug 2008 → Jun 2011 hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Terminated Mixed
Phase 2 NCT00115544 Sep 2005 → Jul 2006 hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Completed No outcome recorded
Phase 2 NCT00004381 Dec 1999 → ? G6PD deficiency, blood group incompatibility, hyperbilirubinemia Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed No outcome recorded
Phase 2 NCT00004382 Dec 1999 → Aug 2007 hyperbilirubinemia Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed No outcome recorded
Phase 2 NCT00004396 Sep 1997 → ? porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02685137 May 2002 → Mar 2003 metabolic disease InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Completed No outcome recorded
Phase not stated1 trial
— NCT00076960 — congenital nonhemolytic jaundice, hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company No longer available No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as stannsoporfin “The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.” NCT00115544 ↗
4

NCT00076960 ↗

NCT00850993 ↗

NCT01887327 ↗

NCT02685137 ↗

Known as B-992 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207 ↗
Known as Estansoporfina ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207 ↗
Known as Mesoporphyrin tin ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207 ↗
Known as Stanate “The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.” NCT00115544 ↗
Known as Stanate (TM) “Stanate (TM) [stannsoporfin, tin-mesoporphyrin]” NCT00076960 ↗
Known as Stannsoporfine ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207 ↗
Known as tin-mesoporphyrin “Stanate (TM) [stannsoporfin, tin-mesoporphyrin]” NCT00076960 ↗
6

NCT00004381 ↗

NCT00004789 ↗

NCT00004382 ↗

NCT00004396 ↗

NCT00004397 ↗

NCT00004398 ↗

Modality Small molecule — CHEMBL4297207 ↗
Route Intravenous “Patients receive tin mesoporphyrin IV as a single dose.” NCT00004396 ↗